Evaluation of the safety of nevirapine therapy during pregnancy

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 5, 2010, Pages 560-562

  Bersoff Matcha, Susan J ^a   Rourke, Daniel ^a   Blank, Jackie ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE;

ADULT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LETTER; LIVER FAILURE; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 77954990576     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181d36024     Document Type: Letter

References (9)

1. Bersoff-Matcha S, Miller W, Mundy LM. Letter of reply to sex differences in nevirapine rash. Clin Infect Dis. 2001;33: 2097-2098.
2. Wong KH, Chan KCW, Lee SS. Sex differences in nevirapine rash. Clin Infect Dis. 2001;33: 2096-2097.
3. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725-735.
4. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7:255-260.
5. Divisions of AIDS Table for Grading Severity of Adult Adverse Experiences. Copyright 1992. AIDS Clinical Trial Group Protocol Management Handbook. August 1, 1998. Edition. Available at: http://rsc.tech-res.com/ Document/safetyandpharma covigilance/SAE-Manual-ACTG-CPCRA-IRP- v02.pdf. Accessed June 24, 2010.
6. Natarajan U, Pym A, McDonald C, et al. Safety of nevirapine in pregnancy. HIV Med. 2007;8: 64-69.
7. Cheeseman SH, Murphy RL, Saag MS, et al. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in [abstract PO-B26-2109]. Presented at: 9th International Conference on AIDS (Amsterdam, June 6-11, 1993). Int Conf AIDS. 1993;9:487.
8. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine therapy in pregnancy. J Acquir Immune Defic Syndr. 2004; 36:772-776
9. Joy S, Poi M, Hughes L, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol. 2005;1032-1038.